Please provide your email address to receive an email when new articles are posted on . Once-monthly subcutaneous octreotide was associated with persistent control of IGF-I and growth hormone levels ...
PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and ...
Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...
Please provide your email address to receive an email when new articles are posted on . Most adults with acromegaly maintained or improved IGF-I levels with oral octreotide in three phase 3 trials.
Significant increases in biochemical response rates were observed in the overall population and in new patients. Treatment with CAM2029, an investigational once-monthly octreotide subcutaneous (SC) ...
PITTSBURGH, Dec. 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced four recent regulatory milestones spanning across all stages of its global pipeline: ...
Viatris Inc. VTRS recently announced four regulatory achievements across multiple stages of its pipeline. These achievements outline the company’s R&D progress in 2025. VTRS will continuously work ...
Syringe and Vials To date, the Company has not received any reports of adverse reactions related to this recall. Mylan Institutional LLC, a Viatris Company, has voluntarily recalled 1 lot of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results